On Tuesday, the EU Commission approved the drug Kesimpta, which was developed by Genmab, as a treatment for sclerosis.
Thus, Genmab's partner Novartis, which currently has the rights to the drug, can start launching the drug in Europe. Hopefully, this will pan out as well as it has in the US, where the drug was approved in late August last year.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.